Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
about
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.Poor survival with wild-type TP53 ovarian cancer?Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent diseaseChaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cellsDietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis.Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway.Tumorigenesis and peritoneal colonization from fallopian tube epithelium.Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancerModest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysisOvarian cancer: genomic analysis.Sorbus rufopilosa Extract Exhibits Antioxidant and Anticancer Activities by Inducing Cell Cycle Arrest and Apoptosis in Human Colon Adenocarcinoma HT29 Cells.
P2860
Q30365539-1BA1EE8A-B4FF-4829-8A31-98757050EF12Q30497303-7405439F-D726-40BE-B60B-4C3995CA2E3EQ33562658-A978EF5C-0C38-4BFE-812F-394E08C82551Q33761535-ADB8AC09-9B7A-4355-85D4-1479327181A0Q33880468-7D4E9076-B425-43DA-9891-F15DBC0E6FB4Q34103978-5FEF5AD9-9D8D-4E33-9A22-DBDC97078CCEQ34411194-977B31AE-1D05-4410-B3D8-3E51ABFCF2F9Q35154556-E7EFE06E-3FA8-40C6-A9E9-1838295668FDQ35766830-2E5FF312-8B69-4434-AC5B-B5C5B27C9F99Q36094088-4F897689-8B8F-4DD3-BD34-C2D0299E810FQ36299733-90184BE6-85FA-447B-A3E3-BB691115C348Q36855239-21E4425A-905E-4FE0-8AE8-67D21E41AB5FQ37269642-686CDAE5-AFB7-4CD3-B0CF-A874CF3B4BA0Q37332480-7AF20E1E-0DA3-4445-B7C1-48316F947A5EQ37552312-2984DAEF-EF63-4ADC-83B8-13195B1F38DF
P2860
Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Associations between p53 overe ...... ecologic Oncology Group study.
@ast
Associations between p53 overe ...... ecologic Oncology Group study.
@en
type
label
Associations between p53 overe ...... ecologic Oncology Group study.
@ast
Associations between p53 overe ...... ecologic Oncology Group study.
@en
prefLabel
Associations between p53 overe ...... ecologic Oncology Group study.
@ast
Associations between p53 overe ...... ecologic Oncology Group study.
@en
P2093
P2860
P1433
P1476
Associations between p53 overe ...... ecologic Oncology Group study.
@en
P2093
Denver Hendricks
Gynecologic Oncology Group
Jeffrey G Bell
John H Farley
John W McBroom
Kathleen M Darcy
R Ilona Linnoila
Robert C Young
Tomas Bonome
William E Brady
P2860
P304
P356
10.1016/J.YGYNO.2008.08.020
P407
P577
2008-10-02T00:00:00Z